ArticleChemMedChem2020
Synthesis of Tamoxifen-Artemisinin and Estrogen-Artemisinin Hybrids Highly Potent Against Breast and Prostate Cancer.
Article in ChemMedChem, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- Artemisinin liposomes regulates breast cancer metastasis and apoptosis through TIGIT/CD155 signal axis.Apoptosis : an international journal on programmed cell death · 2026Article
- The Role of Estrogen Signaling Pathway and Targeted Therapy Exploration in Urological Tumors.International journal of biological sciences · 2026Review
- Phytometabolites as modulators of breast cancer: a comprehensive review of mechanistic insights.Medical oncology (Northwood, London, England) · 2024Review
- Reversal of tamoxifen resistance by artemisinin in ER+ breast cancer: bioinformatics analysis and experimental validation.Oncology research · 2024Article
- Molecular Hybridization as a Strategy for Developing Artemisinin-Derived Anticancer Candidates.Pharmaceutics · 2023Review
- Synthesis of Artesunic Acid-Coumarin Hybrids as Potential Antimelanoma Agents.ACS medicinal chemistry letters · 2023Article
- Crosstalk between ferroptosis and steroid hormone signaling in gynecologic cancers.Frontiers in molecular biosciences · 2023Review
- Modular co-culture engineering of Yarrowia lipolytica for amorphadiene biosynthesis.Microbial cell factories · 2022Article
- Anticancer Drug Conjugates Incorporating Estrogen Receptor Ligands.Pharmaceutics · 2022Review
- Estrogens, Cancer and Immunity.Cancers · 2022Review
- Natural biomolecules and derivatives as anticancer immunomodulatory agents.Frontiers in immunology · 2022Review
- Artemisinin and Derivatives-Based Hybrid Compounds: Promising Therapeutics for the Treatment of Cancer and Malaria.Molecules (Basel, Switzerland) · 2021Review
- Stereoselective Access to Antimelanoma Agents by Hybridization and Dimerization of Dihydroartemisinin and Artesunic acid.ChemMedChem · 2021Article
- Antimalarial and anticancer properties of artesunate and other artemisinins: current development.Monatshefte fur chemie · 2021Review
- Artemisinins as a novel anti-cancer therapy: Targeting a global cancer pandemic through drug repurposing.Pharmacology & therapeutics · 2020Review
- Synthesis of Tamoxifen-Artemisinin and Estrogen-Artemisinin Hybrids Highly Potent Against Breast and Prostate Cancer.ChemMedChem · 2020Article
- Artemisinins as Anticancer Drugs: Novel Therapeutic Approaches, Molecular Mechanisms, and Clinical Trials.Frontiers in pharmacology · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In the search for new and effective treatments of breast and prostate cancer, a series of hybrid compounds based on tamoxifen, estrogens, and artemisinin were successfully synthesized and analyzed for their in vitro activities against human prostate (PC-3) and breast cancer (MCF-7) cell lines. Most of the hybrid compounds exhibit a strong anticancer activity against both cancer cell lines - for example, EC
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.